StockStory highlights iRhythm as a healthcare stock to watch while flagging AdaptHealth and Collegium Pharmaceutical as sells

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory named iRhythm Technologies as a healthcare stock to watch, citing its 23.9% annual revenue growth over two years and a move to positive free cash flow, while recommending investors avoid AdaptHealth and Collegium Pharmaceutical. AdaptHealth saw flat sales and a 12.4% annual decline in earnings per share over five years, with a 0.3% return on capital. Collegium Pharmaceutical's adjusted operating margin fell 6.4 percentage points as costs outpaced revenue, and its returns on capital stagnated. iRhythm trades at 351.1 times forward earnings, AdaptHealth at 11 times, and Collegium at 4.5 times.

Impact on stocks 3

Aging Population▼ · 2 stocks
Adapthealth Corp
AHCO
▼ NegativeCapitalrelevance

Flat sales, 12.4% annual EPS decline, and low 0.3% return on capital flagged as sell.

Biotech & Genomic Medicine▲ · 1 stocks
iRhythm Technologies Inc
IRTC
▲ PositiveCapitalrelevance

23.9% annual revenue growth over two years and move to positive free cash flow highlighted.

© 2026 MarketDXNews